Supplemental Figure S1. Number of subjects enrolled, assessable for the primary endpoint (evaluable), and tested for each marker of ovarian reserve. Subjects are listed by age group and by time point. Baseline 1 post-chemo 1 year post-chemo Age 25-34 Estradiol 5 Estradiol 5 Estradiol 3 Enrolled = 6 FSH 5 5 FSH 5 FSH 3 Evaluable = 5 AMH 5 AMH 5 AMH 3 Inhibin B 5 Inhibin B 5 Inhibin B 3 Age 35-39 Estradiol 8 Estradiol 6 Estradiol 3 Enrolled = 8 FSH 8 FSH 7 FSH 6 Evaluable = 7 AMH 8 AMH 7 AMH 6 Inhibin B 8 Inhibin B 7 Inhibin B 6 Age 40-44 Estradiol 6 Estradiol 7 Estradiol 6 Enrolled = 7 FSH 7 FSH 7 FSH 7 Evaluable = 7 AMH 7 AMH 7 AMH 7 Inhibin B 6 Inhibin B 7 Inhibin B 7 Age 45-50 Estradiol 7 Estradiol 7 Estradiol 6 Enrolled = 8 FSH 7 FSH 7 FSH 6 Evaluable = 8 AMH 7 AMH 7 AMH 6 Inhibin B 7 Inhibin B 7 Inhibin B 6
Supplemental Figure S1. Number of subjects enrolled, assessable for the primary endpoint (evaluable), and tested for each marker of ovarian reserve. Subjects are listed by age group and by time point. Baseline 1 post-chemo 1 year post-chemo Age 25-34 Enrolled = 6 Evaluable = 5 Estradiol FSH 5 AMH Inhibin B 5 5 5 5 Estradiol FSH AMH Inhibin B 5 5 5 5 Estradiol FSH AMH Inhibin B 3 3 3 3 Age 35-39 Enrolled = 8 Evaluable = 7 Estradiol FSH AMH Inhibin B 8 8 8 8 Estradiol FSH AMH Inhibin B 6 7 7 7 Estradiol FSH AMH Inhibin B 3 6 6 6 Age 40-44 Enrolled = 7 Evaluable = 7 Estradiol FSH AMH Inhibin B 6 7 7 6 Estradiol FSH AMH Inhibin B 7 7 7 7 Estradiol FSH AMH Inhibin B 6 7 7 7 Age 45-50 Enrolled = 8 Evaluable = 8 Estradiol FSH AMH Inhibin B 7 7 7 7 Estradiol FSH AMH Inhibin B 7 7 7 7 Estradiol FSH AMH Inhibin B 6 6 6 6
TO13145SupplementalTable1.docx